Repligen (RGEN) Stock Price, News & Analysis

Company Overview

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins. Repligen also produces single-use filtration devices and XCell ATF (alternating tangential flow) systems, which are used to improve cell culture performance and scalability. These products are integrated into manufacturing workflows by contract development and manufacturing organizations, academic research centers and global biopharmaceutical firms.

Over its history, Repligen has expanded through strategic acquisitions and internal product development to broaden its bioprocessing platform. Notable additions include the acquisitions of TangenX for flat-sheet filtration technology and the chromatography resin business from Novasep, enhancing its geographic footprint and product diversity. This growth strategy has enabled Repligen to offer end-to-end solutions from early-stage process development through commercial-scale production.

Repligen serves customers across North America, Europe and Asia, operating manufacturing and research facilities to support a global client base. Under the leadership of President and CEO Matthew Scullin, the company continues to invest in innovation, scaling its operations to meet the evolving demands of the biopharmaceutical industry while maintaining a focus on product quality and customer support.

Key Stats

• Today's Range: $117.14 to $123.00
• 50-Day Range: $111.43 to $134.00
• 52-Week Range: $102.96 to $182.52
• Volume: 621,926 shs
• Average Volume: 775,816 shs
• Market Capitalization: $6.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $166.67
• Consensus Rating: Moderate Buy

Repligen Stock Analysis - MarketRank™

Repligen scored higher than 97% of companies evaluated by MarketBeat, and ranked 45th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Repligen has a consensus price target of $166.67, representing about 39.3% upside from its current price of $119.62.

Amount of Analyst Coverage

Repligen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 37.21%

Earnings Growth

Earnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Repligen is -478.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Repligen is -478.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Repligen has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Repligen has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.81% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Repligen has recently decreased by 7.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Repligen does not currently pay a dividend.

Dividend Growth

Repligen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.33

Percentage of Shares Shorted

6.81% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Repligen has recently decreased by 7.18%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.83

News Sentiment

Repligen has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Repligen this week, compared to 11 articles on an average week.

Search Interest

26 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 767% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Repligen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $201,834.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Repligen is held by insiders.

Percentage Held by Institutions

97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RGEN Stock Analysis - Frequently Asked Questions

How have RGEN shares performed this year?

Repligen's stock was trading at $143.94 at the start of the year. Since then, RGEN stock has decreased by 16.9% and is now trading at $119.6190.

How were Repligen's earnings last quarter?

Repligen Corporation (NASDAQ:RGEN) issued its quarterly earnings data on Tuesday, July, 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by $0.03. Repligen's revenue was up 14.8% compared to the same quarter last year.
Read the conference call transcript.

Does Repligen have any subsidiaries?

Repligen subsidiaries include ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and others.

Who are Repligen's major shareholders?

Repligen's top institutional shareholders include Champlain Investment Partners LLC (2.49%), Invesco Ltd. (2.45%), Sands Capital Management LLC (2.22%) and Brown Capital Management LLC (1.79%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus and Margaret Pax.
View institutional ownership trends.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGEN
• CIK: 730272
• Web: www.repligen.com
• Phone: (781) 250-0111
• Fax: 781-250-0115
• Employees: 1,778
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Repligen: $166.67
• High Price Target: $205.00
• Low Price Target: $130.00
• Potential Upside/Downside: +38.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 70.12
• P/E Growth: 2.1
• Net Income: -$25.51 million
• Net Margins: -2.05%
• Pretax Margin: -2.02%
• Return on Equity: 4.61%
• Return on Assets: 3.24%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 8.59
• Quick Ratio: 7.32

Sales & Book Value

• Annual Sales: $634.44 million
• Price / Sales: 10.69
• Cash Flow: $3.29 per share
• Price / Cash Flow: 36.61
• Book Value: $35.21 per share
• Price / Book: 3.43

Miscellaneous

• Outstanding Shares: 56,260,000
• Free Float: 55,583,000
• Market Cap: $6.79 billion
• Optionable: Optionable
• Beta: 1.07